Get the Stockscreener App
0.00
100.00%
-7.87
After Hours:
7.87
7.87
+
Chromadex Corp stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.
See More
Previous Close:
$7.87
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$594.49M
Revenue:
$83.57M
Net Income/Loss:
$-4.94M
P/E Ratio:
0.00
EPS:
-0.07
Net Cash Flow:
$6.97M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$9.18
Chromadex Corp Stock (CDXC) Company Profile
Name
Chromadex Corp
Sector
Industry
Phone
310-388-6706
Address
10900 WILSHIRE BLVD, LOS ANGELES
Compare CDXC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXC
Chromadex Corp
|
0.00 | 594.49M | 83.57M | -4.94M | 6.97M | -0.07 |
|
KHC
Kraft Heinz Co
|
29.64 | 35.99B | 25.85B | 2.74B | 3.02B | 2.26 |
|
GIS
General Mills Inc
|
56.39 | 31.49B | 19.64B | 2.56B | 2.48B | 4.55 |
|
K
Kellanova
|
82.77 | 28.46B | 12.75B | 1.34B | 1.13B | 3.87 |
|
MKC
Mccormick Co Inc
|
75.01 | 20.20B | 6.68B | 792.60M | 774.40M | 2.94 |
|
HRL
Hormel Foods Corp
|
30.19 | 16.82B | 11.92B | 805.04M | 1.01B | 1.46 |
Chromadex Corp Stock (CDXC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-11-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Oct-16-19 | Initiated | Oppenheimer | Outperform |
| Feb-14-19 | Initiated | B. Riley FBR | Buy |
| Nov-27-17 | Resumed | H.C. Wainwright | Buy |
| Sep-25-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-03-17 | Initiated | Rodman & Renshaw | Buy |
View All
Chromadex Corp Stock (CDXC) Latest News
ChromaDex (NASDAQ:CDXC) Coverage Initiated by Analysts at StockNews.com - Defense World
Niagen Bioscience Confirms Its Operations Remain Unaffected By New Tariffs - MarketScreener
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs - Business Wire
Niagen Says Its Operations Remain Resilient Amid Recent Tariff Developments - MarketScreener
Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments - BioSpace
Niagen Bioscience maintains stability amid tariffs By Investing.com - Investing.com India
Niagen Bioscience maintains stability amid tariffs - Investing.com Australia
ChromaDex (NASDAQ:CDXC) Coverage Initiated at StockNews.com - Defense World
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® - MarketScreener
H.C. Wainwright holds $11 target on Niagen Bioscience stock By Investing.com - Investing.com Australia
H.C. Wainwright holds $11 target on Niagen Bioscience stock - Investing.com
Why ChromaDex Corp (CDXC) Is Surging In 2025? - Insider Monkey
Botanical Supplements Market In-depth Insights, Business - openPR.com
Why These 15 Defensive Stocks Are Surging In 2025 - Insider Monkey
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) - Marketscreener.com
Niagen Bioscience secures new patent for NAD+ precursors - Investing.com India
Niagen Bioscience broadens NAD+ precursor IP portfolio with new patent - TipRanks
Niagen Bioscience secures new patent for NAD+ precursors By Investing.com - Investing.com UK
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms - Business Wire
ChromaDex Completes Name Change to Niagen Bioscience -March 19, 2025 at 09:29 am EDT - Marketscreener.com
Chromadex Rebrands to Niagen Bioscience, Inc. - TipRanks
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science - The Bakersfield Californian
Chlorinated Isopropane Market Set for 4.9% CAGR Growth, Hitting USD 496.0 Million by 2035 | Fact.MR Report - GlobeNewswire Inc.
ChromaDex Corporation will Change its Name to Niagen Bioscience, Inc -March 19, 2025 at 12:00 am EDT - Marketscreener.com
ChromaDex’s (CDXC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
ChromaDex changes name to Niagen Bioscience to home in on healthy aging - SupplySide Supplement Journal
Chromadex’s Strategic Rebranding and Promising Clinical Developments Justify Buy Rating - TipRanks
ChromaDex rebrands as Niagen Bioscience to reflect growth in supplement, pharmaceutical industries - NutraIngredients-USA.com
ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+ - insights.citeline.com
ChromaDex to rebrand as Niagen Bioscience and change ticker By Investing.com - Investing.com Australia
Q1 Earnings Forecast for ChromaDex Issued By HC Wainwright - Defense World
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - BioSpace
ChromaDex to rebrand as Niagen Bioscience and change ticker - Investing.com India
Major Rebrand: ChromaDex Evolves to Niagen Bioscience, Sharpens Focus on Aging Science - StockTitan
ChromaDex to Present at the 37th Annual Roth Conference - BioSpace
Healthy Aging Leader ChromaDex Takes Center Stage at ROTH Conference Longevity Panel - StockTitan
ChromaDex (NASDAQ:CDXC) Given New $11.00 Price Target at HC Wainwright - Defense World
ChromaDex stock price target raised to $11 by H.C. Wainwright - Investing.com Australia
Chromadex corp. SVP buys $2,145 worth of common stock - Investing.com
ChromaDex Co. (NASDAQ:CDXC) Shares Bought by Rhumbline Advisers - Defense World
Truist Financial Corp Makes New $54,000 Investment in ChromaDex Co. (NASDAQ:CDXC) - Defense World
StockNews.com Downgrades ChromaDex (NASDAQ:CDXC) to Buy - Defense World
ChromaDex (NASDAQ:CDXC) Stock Price Expected to Rise, LADENBURG THALM/SH SH Analyst Says - Defense World
Chromadex Corp Stock (CDXC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):